[1]粟琮皓,姜志友,谢 胜,等.非小细胞肺癌免疫微环境近十年热点CiteSpace分析[J].医学信息,2025,38(05):53-61.[doi:10.3969/j.issn.1006-1959.2025.05.008]
　SU Conghao,JIANG Zhiyou,XIE Sheng,et al.CiteSpace Analysis of Hotspots in Immune Microenvironment of Non-small Cell Lung Cancer in Recent Ten Years[J].Journal of Medical Information,2025,38(05):53-61.[doi:10.3969/j.issn.1006-1959.2025.05.008]
点击复制

非小细胞肺癌免疫微环境近十年热点CiteSpace分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年05期
页码:
53-61
栏目:
医学数据科学
出版日期:
2025-03-01

文章信息/Info

Title:
CiteSpace Analysis of Hotspots in Immune Microenvironment of Non-small Cell Lung Cancer in Recent Ten Years
文章编号:
1006-1959（2025）05-0053-09
作者:
粟琮皓1; 姜志友1; 谢 胜2; 方 芳3; 董芷辛3; 吕梦玉3; 石 玮3
1.广西中医药大学第一临床医学院，广西 南宁 530000；2.广西中医药大学第一附属医院治未病中心，广西 南宁 530023；3.广西中医药大学第一附属医院肿瘤二病区，广西 南宁 530023
Author(s):
SU Conghao1;  JIANG Zhiyou1;  XIE Sheng2;  FANG Fang3;  DONG Zhixin3;  LYU Mengyu3;  SHI Wei3
1.The First Clinical Medical College of Guangxi University of Chinese Medicine, Nanning 530000, Guangxi, China;2.Preventive Treatment Center, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, Guangxi, China;3.The Second Ward of Tumor Department, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, Guangxi, China
关键词:
非小细胞肺癌; 免疫微环境; CiteSpace; 文献计量学; 可视化分析
Keywords:
Non-small cell lung cancer;  Immune microenvironment;  CiteSpace;  Bibliometrics;  Visual analysis
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2025.05.008
文献标志码:
A
摘要:
目的 探讨近十年非小细胞肺癌免疫微环境相关研究的发展趋势和热点，为该领域发展提供参考。方法 利用中国知网（CNKI）和Web of Science（WOS）核心合集数据对2013-2023年发表的与非小细胞肺癌免疫微环境相关的中、英文文献进行了系统检索，随后运用CiteSpace6.2软件对这些文献的国家、机构、作者合作、关键词共现、关键词聚类、关键词突显进行分析并可视化。结果 共纳入321篇中文文献，999篇英文文献，研究文献数量呈快速增长趋势，尤其2020年之后增速更为明显，论文数量呈现出爆发性增长（增幅约61%）。作者合作可视化分析显示国外作者之间较国内作者联系紧密，均可见形成密集的小团体。机构可视化分析显示国外机构相对于国内机构拥有更多发文量，国家可视化分析显示我国在该领域的发文量位于全球首位。关键词共现分析显示当前研究热点集中在预后、免疫治疗等方面，聚类分析发现主要类别包括免疫治疗、预后、肠道菌群、缺氧等，关键词突现分析显示研究关注重点早期更关注药物安全性评估，近年来逐渐转向关注微环境、基因调控、肿瘤进展等机制方面。结论 非小细胞肺癌免疫微环境研究正处于快速发展期，研究视角也在不断深入。当前研究重点是解析肿瘤微环境的免疫抑制机制、肿瘤相关免疫细胞的功能状态，以及相关信号通路和基因的调控，这些研究有助于优化和开发免疫治疗策略。
Abstract:
Objective To explore the development trend and hotspots of immune microenvironment related research in non-small cell lung cancer in recent ten years, and to provide reference for the development of this field. Methods The Chinese and English literatures related to the immune microenvironment of non-small cell lung cancer published from 2013 to 2023 were systematically searched by using the core collection data of CNKI and Web of Science (WOS). Then, CiteSpace6.2 software was used to analyze and visualize the countries, institutions, author cooperation, keyword co-occurrence, keyword clustering and keyword highlighting of these literatures. Results A total of 321 Chinese literatures and 999 English literatures were included. The number of research literatures showed a rapid growth trend, especially after 2020, and the number of literatures showed an explosive growth (an increase of about 61%). The visual analysis of author cooperation showed that compared with domestic authors, foreign authors were more closely linked and formed dense small groups. Visualization analysis of institutions showed that foreign institutions had more publications than domestic institutions. National visualization analysis showed that China’s number of literatures in this field ranked first in the world. Keyword co-occurrence analysis showed that the current research hotspots focused on prognosis, immunotherapy, etc. Cluster analysis showed that the main categories included immunotherapy, prognosis, intestinal flora, hypoxia, etc. Keyword burst analysis showed that the focus of research was more on drug safety assessment in the early stage, and gradually shifted to the mechanisms of microenvironment, gene regulation and tumor progression in recent years. Conclusion The research on the immune microenvironment of non-small cell lung cancer is in a period of rapid development, and the research perspective is also deepening. The current research focuses on analyzing the immunosuppressive mechanism of tumor microenvironment, the functional status of tumor-associated immune cells, and the regulation of related signaling pathways and genes, these studies are helpful to optimize and develop immunotherapy strategies.

参考文献/References:

[1]Duma N,Santana-Davila R,Molina JR.Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.[2]Remon J,Pignataro D,Novello S,et al.Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer[J].Cancer Treat Rev,2021,95:102178.[3]朱彦,李嘉琪,常青,等.新辅助免疫治疗对可切除的非小细胞肺癌患者肺功能的影响及疗效分析[J].中华医学杂志,2022,102(6):393-398.[4]Asadi M,Zarredar H,Zafari V,et al.Immune Features of Tumor Microenvironment: A Genetic Spotlight[J].Cell Biochem Biophys,2024,82(1):107-118.[5]Pellinen T,Paavolainen L,Martín-Bernabé A,et al.Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features[J].J Natl Cancer Inst,2023,115(1):71-82.[6]汤正波,沈玉光,舒德军.癌相关成纤维细胞源性SULF1对非小细胞肺癌细胞生物学行为的影响和机制[J].现代肿瘤医学,2023,31(21):3933-3938.[7]You D,Wang D,Wu Y,et al.Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study[J].BMC Med,2022,20(1):203.[8]G?覿hler A,Trufa DI,Chiriac MT,et al.Glucose-Restricted Diet Regulates the Tumor Immune Microenvironment and Prevents Tumor Growth in Lung Adenocarcinoma[J].Front Oncol,2022,12:873293.3[9]Chen C.CiteSpaceⅡ: Detecting and visualizing emerging trends and transient patterns in scientific literature[J].Journal of the American Society for Information Science and Technology,2006,57(3):359-377.[10]Liu CS,Wei Y,Danesh Yazdi M,et al.Long-term association of air pollution and incidence of lung cancer among older Americans: A national study in the Medicare cohort[J].Environ Int,2023,181:108266.[11]Zhang Y,Vaccarella S,Morgan E,et al.Global variations in lung cancer incidence by histological subtype in 2020: a population-based study[J].Lancet Oncol,2023,24(11):1206-1218.[12]刘磊,黄诚,李力,等.循环肿瘤细胞中不同表型细胞FGFR1基因表达程度与非小细胞肺癌临床病理特点相关性研究[J].中国肺癌杂志,2018,21(5):365-374.[13]Biton J,Mansuet-Lupo A,Pécuchet N,et al.TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma[J].Clin Cancer Res,2018,24(22):5710-5723.[14]Koyama S,Akbay EA,Li YY,et al.STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment[J].Cancer Res,2016,76(5):999-1008.[15]Qian Y,Galan-Cobo A,Guijarro I,et al.MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma[J].Cancer Cell,2023,41(7):1363-1380.e7.[16]Skoulidis F,Goldberg ME,Greenawalt DM,et al.STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma[J].Cancer Discov,2018,8(7):822-835.[17]孙清玙,周阳,杜丽娟,等.巨噬细胞相关基因与非小细胞肺癌预后和肿瘤微环境的分析[J].遗传,2023,45(8):684-699.[18]郭雪茹.miR-101减弱肿瘤相关成纤维细胞促转移作用及抑制非小细胞肺癌侵袭转移的机制研究[D].天津:天津医科大学,2020.[19]李道卫.髓源性抑制细胞在非小细胞肺癌免疫逃逸的作用机制研究[D].济南:山东大学,2018.[20]St Paul M,Ohashi PS.The Roles of CD8+ T Cell Subsets in Antitumor Immunity[J].Trends Cell Biol,2020,30(9):695-704.[21]Mantovani A,Marchesi F,Malesci A,et al.Tumour-associated macrophages as treatment targets in oncology[J].Nat Rev Clin Oncol,2017,14(7):399-416.[22]Balta E,Wabnitz GH,Samstag Y.Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors[J].Int J Mol Sci,2021,22(11):5736.[23]Winograd R,Byrne KT,Evans RA,et al.Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma[J].Cancer immunology research,2015,3(4): 399-411.[24]张曼,杨涛,石洋,等.DCs-CIK细胞免疫治疗联合化疗对晚期非小细胞肺癌疗效及安全性的影响[J].肿瘤,2014,34(04):361-365.[25]武雪.联合WEE1和ATR抑制剂协同αPD-L1增强抗肿瘤效应的机制研究[D].武汉:华中科技大学,2022.[26]仵红娇,刘春玲,金叶,等.非小细胞肺癌中WASF1基因与免疫细胞浸润的相关性分析[J].临床与实验病理学杂志,2022,38(8):936-942.[27]Voigt W,Manegold C,Pilz L,et al.Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer[J].Curr Opin Oncol,2020,32(1):68-77.[28]周彩存,蒋涛.肺癌与精准医疗[J].肿瘤,2016,36(4):365-371.[29]Yang CY,Yang JC,Yang PC.Precision Management of Advanced Non-Small Cell Lung Cancer[J].Annu Rev Med,2020,71:117-136.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(05):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(05):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(05):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(05):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(05):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(05):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(05):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(05):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[9]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(05):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
[10]杨珑静,马洪波,张献全.抗血管生成药物在非小细胞肺癌中的应用及研究进展[J].医学信息,2019,32(08):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]
　YANG Long-jing,MA Hong-bo,ZHANG Xian-quan.Application and Research Progress of Anti-angiogenic Drugs in Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(05):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]

更新日期/Last Update: 1900-01-01